Treatment of hereditary angioedema with normal C1-inhibitor with icatibant, a selective bradykinin B2 receptor antagonist

被引：0

作者：

Bork, K. ^{[1
]}

机构：

[1] Univ Hosp Mainz, Dept Dermatol, Mainz, Germany

来源：

ALLERGY | 2011年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

1111

引用

页码：427 / 428

页数：2

共 50 条

[1] Icatibant, a Selective Bradykinin B2 Receptor Antagonist Used in Hereditary Angioedema Due to C1 Inhibitor Deficiency
Bork, K.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : AB165 - AB165
[2] Treatment of hereditary angioedema due to C1 inhibitor deficiency with Icatibant, a selective bradykinin B2 receptor antagonist: a safety perspective
Bork, K.
[J]. ALLERGY, 2008, 63 : 47 - 47
[3] Treatment for hereditary angioedema with the bradykinin (B2) receptor antagonist Icatibant (JE 049)
Rosenkranz, B
Meng, G
Knolle, J
Bork, K
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 : 166 - 167
[4] A case series about the treatment of hereditary angioedema due to C1 inhibitor deficiency with icatibant, a selective bradykinin B2 receptor antagonist
Bork, K.
[J]. ALLERGY, 2010, 65 : 455 - 455
[5] Icatibant, a new bradykinin B2 receptor antagonist, for hereditary angioedema attacks
Reshef, A.
Liebovich, I.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S102 - S102
[6] Safety Evaluation of Icatibant, a Selective Bradykinin B2 Receptor Antagonist Used in Hereditary Angioedema Due to C1 Inhibitor Deficiency
Staubach, P.
Bork, K.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S100 - S100
[7] Acquired angioedema due to C1 inhibitor deficiency treated with icatibant, a selective bradykinin B2 receptor antagonist
Bork, K.
[J]. ALLERGY, 2011, 66 : 109 - 109
[8] Treatment of idiopathic nonhistaminergic angioedema with bradykinin B2 receptor antagonist icatibant
Del Corso, I.
Puxeddu, I.
Sardano, E.
Geraci, S.
Breggia, M.
Rocchi, V.
Migliorini, P.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2012, 108 (06) : 460 - 461
[9] Icatibant, a potent and selective bradykinin B2 receptor antagonist, is effective in treating patients with Hereditary Angioedema (HAE)
Levy, R. J.
Goodman, S.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) : S277 - S277
[10] The efficacy and safety of Icatibant, a selective bradykinin B2 receptor antagonist, for treating the symptoms of hereditary angioedema attacks
Cicardi, M.
[J]. ALLERGY, 2008, 63 : 474 - 474

← 1 2 3 4 5 →